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The concept of global vascular risk is recognized as an important predictor
of major events in patients with coronary artery disease.
We aimed to evaluate long term clinical outcome among patients with
peripheral vascular disease (PVD) following coronary artery bypass grafting.
We studied 589 consecutive patients who underwent isolated coronary
artery bypass grafting between January 2003 and June 2005. The impact of
peripheral artery disease was assessed by comparing a two year follow-up of
2 groups of patients: patients with (n=243) and without (n=346) PVD.
Patients with PVD were significantly older (70±9 vs 64±11 years p<0.001)
and were more often men (80.3% vs 74.2% p=0.04) than those without PVD.
They had a higher incidence of hypertension (p=0.002), chronic renal dysfunc-
tion (p<0.01), chronic pulmonary disease (p=0.005) with higher EuroSCORE
cardiac risk (9.6±6 vs 3.8±3 p<0.01). No significant difference was noted
between the 2 groups with regard to left ventricular ejection fraction.
The analysis of ischemic events showed that peripheral ischemic events
(19.7% vs 4.6% p<0.001) and more specifically cerebrovascular events (9% vs
3.5% p<0.01) were significantly higher in PVD group. Neither myocardial inf-
arction (6.2% vs 6.7% p=ns) nor new coronary revascularization (9.8% vs
14.5% p=ns) differed significantly among the 2 groups;
The two-year follow up showed a rate of survival markedly lower for patents
with PVD than those with isolated coronary disease. Two-year cumulative sur-
vival rates were 76.6% for patients with PVD and 94.1% for those with iso-
lated coronary disease (p<0.001).
Differences in outcome remained significant after adjusting all variables
including medical treatment, PVD appeared as an independent predictive
factor of all cause mortality with a hazard ration of 3.2 [95%CI (1.8-5.7)
p<0.001].
PVD was not only highly prevalent but also strongly associated with long
term mortality after coronary artery bypass surgery.
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Background: In the western countries, a high prevalence of lower-extrem-
ities peripheral artery disease (LE-PAD) is reported in the elderly. The epide-
miological transition in the developing countries might also involve this
affection, but data regarding LE-PAD in Sub-Saharan Africa are unknown. We
sought to determine the prevalence and risk factors for LE-PAD in the general
elder population in 2 Sub-Saharan African countries: Congo and Central
African Republic.
Methods: We performed 2 cross-sectional studies in the populations aged
>65 years in two representative districts of Brazzaville, Congo and Bangui,
Central African Republic. Demographic data, as well as medical history, were
collected along with clinical and biological data to determine the traditional
cardiovascular disease risk factors. The ankle-brachial index (ABI) was used
to define LE-PAD, when ABI <0.90. An ABI >1.40 was considered to define
medial calcinosis (MC).
Results: Among the 997 participants (age 73.6+6.5 yrs, 40.7% males), 239
(24.0%) had LE-PAD, while 69 (6.9%) had MC. Adjusted for age, gender and
study site, factors significantly associated with LE-PAD were hypertension
(OR=1.75, 95%CI: 1.24-2.48, p=0.002) and daily alcohol consumption
(OR=0.72, 95%CI: 0.53-0.98, p=0.04). A borderline association was found with
a body-mass index >30kg/m2 (OR=1.56, 95%CI: 0.95-2.58, p=0.08). Of note,
neither smoking nor diabetes were found as significant associated risk factors.
Adjusted for age, gender and study site, factors significantly associated with
MC were schooling (vs. no school education, OR=3.20, 95%CI: 1.69-6.04,
p=0.0003) and hypertension (OR=0.38, 95%CI: 0.22-0.66, p=0.0006), while
alcohol consumption (OR=0.63, 95%CI: 0.37-1.07, p=0.09) and heart rate
(OR=1.23, 95%CI: 0.98-1.56, p=0.07) presented a borderline association.
Conclusions: In this first population study in Central Africa, we found a
very high prevalence of LE-PAD in the elderly, and highlight particularities
regarding the associated risk factors, different from data published in western
countries.
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Background: In the EUROPA study, perindopril 8 mg/day significantly
reduced the combined primary end point (PEP) of cardiovascular death, non-
fatal myocardial infarction (MI), and/or resuscitated cardiac arrest by 20%,
compared with placebo, after 4.2 years in 12 218 patients with stable coronary
artery disease (CAD) without heart failure. The aim of this new analysis is to
calculate the benefits of perindopril 8 mg/day in CAD patients with hyperten-
sion according to JNC-7 cutoff.
Methods: In EUROPA, 7064 (57.8%) patients were hypertensive with
SBP/DBP ≥ 140/90 mm Hg or current antihypertensive therapy. The baseline
characteristics of these patients were not different from the whole EUROPA
population: 63% had a previous MI (n=4469) and 54% were previously revas-
cularized (n=3839).
Results: In EUROPA patients with hypertension, the incidence of the PEP
with perindopril (n=3506) and placebo (n=3558) was 9% and 11.1%, respec-
tively. The relative risk reduction (RRR) of PEP with perindopril was 18.6%
(95% CI [6.9; 30.8]; P=0.004).
Among EUROPA patients with hypertension, the RRR of fatal and nonfatal
MI was 26.4% (95% CI [11.6; 38.8]; P=0.001), with a rate of 5.6% and 7.6%
with perindopril and placebo, respectively. This reduction in risk for MI was
consistent whether the patients had had previous MI (RRR, 32.6% [95% CI
(16; 45.9); P<0.001]) or revascularization (RRR, 30.2%, [95% CI (7.7; 47.2);
P=0.011]).
Finally, heart failure was significantly reduced with perindopril (1.2%)
versus placebo (2%) by 40.2% (95% CI [12.4; 59.2]; P=0.008). In these CAD
patients with hypertension, discontinuation for hypotension was particularly
low with perindopril (0.6%), similar to placebo (0.2%), confirming the safety
of high-dose perindopril (8 mg/day) in terms of BP lowering.
Conclusions: In the EUROPA study, the benefit with perindopril 8 mg/day
was consistent among hypertensive CAD patients, even in case of previous MI
and/or revascularization. These results are in line with the 2006 ESC guide-
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lines on the management of stable angina pectoris, endorsing the use of this
dose of perindopril, which is of proven efficacy in this indication (Class 1,
level of evidence A)
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Introduction: Heart rate turbulence (HRT) has been currently believed to
represent a non invasive method of measurement of the baroreflex-sensitivity.
Studies suggested that it may reflect vagal robustness in antagonizing the
effects of sympathic activity.
Most studies exploring HRT have been dealt in ischemic and heart failure
patients. To date, only few studies investigated these parameters in patients
with hypertension.
Aim: the aim of this study is to compare HRT parameters, derived from
Holter recordings, in hypertensive patients and healthy controls.
Methods: In this prospective studies, 85 patients with essential hyperten-
sion (45 females and 40 males, age 60 ± 12 years old) and 40 healthy controls
matched to age and gender underwent Holter recordings with analysis of HRT
parameters: turbulence onset (TO) and turbulence slope (TS). Heart rate vari-
ability parameters reflecting sympathic (SDNN, SDANN, LF) and parasympa-
thic activity (RMSSD, HF) were also studied. Patients with diabetes, ischemic
heart disease and atrial fibrillation were excluded.
Results: there was no significant difference regarding HRT parameters as
well as RMSSD and HF between hypertensive patients and healthy controls.
SDNN, SDANN and LF were significantly lower in hypertensive patients
(table 1). This difference persisted after multivariate analysis.
Table. Comparison between HRT and HRV parameters in hypertensive 
patients and healthy controls 
Conclusion: HRT parameters are similar in essential hypertensive patients
and healthy controls. Other Holter derived parameters exploring the parasym-
pathic tone were also comparable suggesting that the vagal tone is preserved
in essential hypertension. This latter is associated with a significant higher
sympathetic activity. Further studies are needed to determine the pathophysio-
logic significance and the prognostic value of this loss of modulation of the
autonomic nervous system and whether it could have therapeutic implications.
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A Neurotrophin (NT): Brain-derived Neurotrophic Factor (BDNF) and the
tropomyosin-related kinase (TrK) family of receptors play an important role in
regulating vascular development and response to injury. But little is known about
their role in vascular homeostasis in normal and pathological conditions. In the
present study, we investigated the potential participation of the BDNF/TrK
pathway and oxidative stress during the development of hypertension in an Spon-
taneously Hypertensive Rat (SHR) model. Systolic blood pressure (SBP) was
measured (tail-cuff method) in male SHR and normotensive Wistar Kyoto rats
(WKY) at 6 and 13 weeks of age. Plasma antioxidant capacity was measured by
Electron Spin Resonance. Production of superoxide anion was assessed in aorta
slices using a fluorescent oxidative probe: dihydroethidium.(DHE) Aorta
NAD(P)H oxidase activity was determined by chemiluminescence. Plasma level
of BDNF was assessed by an ELISA method and expression of BDNF, TrKB,
p47phox, Angiotensin II AT1 receptor and MCP-1 was determined by immu-
nochemistry. At 13 weeks, SHR became hypertensive (p<0.05). In 6-week-old
SHR aorta, DHE staining was twice than in WKY aorta and the same pattern was
observed at 13 weeks. At 13 weeks, NAD(P)H oxidase activity enhancement was
associated with an increase in p47phox and AT1 expression and BDNF in aortic
wall (p<0.05). Vascular MCP-1 expression increased with increasing blood pres-
sure (p<0.05). In SHR rats, an increase in levels of oxidative stress occurs before
elevation of blood pressure, but is not linked with an increase in NAD(P)H oxi-
dase activity at 6 weeks. However, this oxidative stress seems to be associated
with an increase in vascular BDNF during animals aging, and appears prema-
turely in SHR vessels. The relationship between BDNF/TrKB, oxidative stress
and inflammation occurring in hypertension onset, remains to be elucidated.
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Background: Aortic dissection is a well rare disease with pour mid and
long term prognosis. The treatment of initial phase of acute aortic syndrom
(AAS) affecting the descending aorta is essentially based on lowering blood
pressure and on relieving pain. The emergence of endovascular therapy offers
new perspectives in the management of this old disease. Few data exist on the
long term prognosis of patients who discharge alive after a medical treatment
of a type B AAS. The aim of our study was to determine factors of the acute
phase associated with adverse long term survival.
Methods and Results: We study the long term outcome of 77 patients, hos-
pitalized in our center from 1996 to 2008, who discharge alive after type B AAS.
All patients received a medical treatment and an endovascular therapy if needed.
The mean follow-up period was 50.8 month, with a survival rate of 78 %.
Kaplan-Meier survival curves were constructed, and Cox proportional haz-
ards analysis was performed to identify independent predictors of follow-up
mortality from any cause.
Factors that influence the mortality (p<0.05) was a low systolic blood pres-
sure at admission, a thrombopenia in the acute period, a prior history of
COPD, the diameter of the ascending aorta and the take of a inhibitor of the
renin-angiotensin system. Independent predictors of follow-up mortality from
all cause were the history of COPD (p=0.0022, HR 17.5) a thrombopenia in
the acute phase (p=0.042, HR 3.5), and systolic blood pressure at admission
under 120 mmHg (p=0.0048, HR 7.928).
Conclusion: Patients who discharge alive after medically treated type B
acute aortic disease keep a worse mid and long term prognosis. Our study
identifies new risk factors of mortality after discharge, and a population at
very high risk. The treatment of the acute phase needs further study to better
understand and optimize care of this patients.
 Hypertensive patients 
(n=85)
Healthy controls 
(n=40)
p
TO -0.0196 -0.0120 NS
TS 8,66 9,68 NS
SDNN 117 ± 33 141 ± 45 0.001
SDANN 101 ± 29 125 ± 42 <0.0001
RMSSD 37 ± 22 44 ± 20 NS
LF 564 ± 53 830 ± 60 0.02
HF 301 ± 34 436 ± 40 NS
